Table of Contents
International Journal of Proteomics
Volume 2014 (2014), Article ID 390781, 12 pages
http://dx.doi.org/10.1155/2014/390781
Research Article

Combined Phosphoproteomics and Bioinformatics Strategy in Deciphering Drug Resistant Related Pathways in Triple Negative Breast Cancer

1Gonda/UCLA Breast Cancer Research Laboratory and the Revlon/UCLA Breast Center, Department of Surgery, David Geffen School of Medicine, University of California at Los Angeles, 200 Med Plaza, Ste B265-1, Los Angeles, CA 90095-7028, USA
2The Pasarow Mass Spectrometry Laboratory, NPI-Semel Institute, University of California at Los Angeles, Los Angeles, CA, USA

Received 21 July 2014; Revised 21 October 2014; Accepted 22 October 2014; Published 13 November 2014

Academic Editor: Jen-Fu Chiu

Copyright © 2014 Xinyu Deng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2013,” CA Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11–30, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Autier, M. Boniol, C. la Vecchia et al., “Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database,” BMJ, vol. 341, p. c3620, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Boyle, “Triple-negative breast cancer: epidemiological considerations and recommendations,” Annals of Oncology, vol. 23, no. 6, pp. vi7–vi12, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Criscitiello, H. A. Azim Jr., P. C. Schouten, S. C. Linn, and C. Sotiriou, “Understanding the biology of triple-negative breast cancer,” Annals of Oncology, vol. 23, supplement 6, pp. vi13–vi18, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Oakman, G. Viale, and A. Di Leo, “Management of triple negative breast cancer,” Breast, vol. 19, no. 5, pp. 312–321, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Penault-Llorca and G. Viale, “Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective,” Annals of Oncology, vol. 23, supplement 6, pp. vi19–vi22, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Mccarthy, G. Mitchell, M. Bilous, N. Wilcken, and G. J. Lindeman, “Triple-negative breast cancer: making the most of a misnomer,” Asia-Pacific Journal of Clinical Oncology, vol. 8, no. 2, pp. 145–155, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Gelmon, R. Dent, J. R. Mackey, K. Laing, D. Mcleod, and S. Verma, “Targeting triple-negative breast cancer: optimising therapeutic outcomes,” Annals of Oncology, vol. 23, no. 9, Article ID mds067, pp. 2223–2234, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Bayraktar and S. Glück, “Molecularly targeted therapies for metastatic triple-negative breast cancer,” Breast Cancer Research and Treatment, vol. 138, no. 1, pp. 21–35, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. F. André and C. C. Zielinski, “Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents,” Annals of Oncology, vol. 23, supplement 6, Article ID mds195, pp. vi46–vi51, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Gámez-Pozo, N. I. Ferrer, E. Ciruelos et al., “Shotgun proteomics of archival triple-negative breast cancer samples,” Proteomics—Clinical Applications, vol. 7, no. 3-4, pp. 283–291, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Cabezón, I. Gromova, P. Gromov et al., “Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer,” Molecular & Cellular Proteomics, vol. 12, no. 2, pp. 381–394, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Hunter, “Signaling—2000 and beyond,” Cell, vol. 100, no. 1, pp. 113–127, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. J. V. Olsen, B. Blagoev, F. Gnad et al., “Global, in vivo, and site-specific phosphorylation dynamics in signaling networks,” Cell, vol. 127, no. 3, pp. 635–648, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Macek, M. Mann, and J. V. Olsen, “Global and site-specific quantitative phosphoproteomics: principles and applications,” Annual Review of Pharmacology and Toxicology, vol. 49, pp. 199–221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. T. E. Thingholm, O. N. Jensen, and M. R. Larsen, “Analytical strategies for phosphoproteomics,” Proteomics, vol. 9, no. 6, pp. 1451–1468, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M. E. Stearns, M. Wang, Y. Hu, and F. U. Garcia, “Interleukin-10 activation of the interleukin-10E1 pathway and tissue inhibitor of metalloproteinase-1 expression is enhanced by proteasome inhibitors in primary prostate tumor lines,” Molecular Cancer Research, vol. 1, no. 9, pp. 631–642, 2003. View at Google Scholar · View at Scopus
  18. C. Börner, M. Smida, V. Höllt, B. Schraven, and J. Kraus, “Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling,” The Journal of Biological Chemistry, vol. 284, no. 51, pp. 35450–35460, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Oyama, T. Nagashima, T. Suzuki et al., “Integrated quantitative analysis of the phosphoproteome and transcriptome in tamoxifen-resistant breast cancer,” Journal of Biological Chemistry, vol. 286, no. 1, pp. 818–829, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. B. N. Rexer, A.-J. L. Ham, C. Rinehart et al., “Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition,” Oncogene, vol. 30, no. 40, pp. 4163–4174, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Oliveras-Ferraros, A. Vazquez-Martin, E. López-Bonet et al., “Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer,” International Journal of Oncology, vol. 33, no. 6, pp. 1165–1176, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. R. M. Neve, K. Chin, J. Fridlyand et al., “A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes,” Cancer Cell, vol. 10, no. 6, pp. 515–527, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. B. D. Lehmann, J. A. Bauer, X. Chen et al., “Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies,” Journal of Clinical Investigation, vol. 121, no. 7, pp. 2750–2767, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. S. A. Beausoleil, J. Villén, S. A. Gerber, J. Rush, and S. P. Gygi, “A probability-based approach for high-throughput protein phosphorylation analysis and site localization,” Nature Biotechnology, vol. 24, no. 10, pp. 1285–1292, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Snel, G. Lehmann, P. Bork, and M. A. Huynen, “String: a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene,” Nucleic Acids Research, vol. 28, no. 18, pp. 3442–3444, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Caraux and S. Pinloche, “PermutMatrix: a graphical environment to arrange gene expression profiles in optimal linear order,” Bioinformatics, vol. 21, no. 7, pp. 1280–1281, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. P. den Hollander, M. I. Savage, and P. H. Brown, “Targeted therapy for breast cancer prevention,” Frontiers in Oncology, vol. 3, article 250, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Lu, S. A. Whelan, J. He et al., “Hydrophobic proteome analysis of triple negative and hormone-receptor-positive-her2-negative breast cancer by mass spectrometer,” Clinical Proteomics, vol. 6, no. 3, pp. 93–103, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Watanabe and H. Osada, “Phosphorylation-dependent protein-protein interaction modules as potential molecular targets for cancer therapy,” Current Drug Targets, vol. 13, no. 13, pp. 1654–1658, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Ishihama and M. Wakabayashi, “Phosphoproteomics -based cancer molecular-targeting therapy and diagnostics,” Gan To Kagaku Ryoho, vol. 39, no. 7, pp. 1019–1025, 2012. View at Google Scholar · View at Scopus
  31. D. A. Megger, T. Bracht, H. E. Meyer, and B. Sitek, “Label-free quantification in clinical proteomics,” Biochimica et Biophysica Acta: Proteins and Proteomics, vol. 1834, no. 8, pp. 1581–1590, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. V. J. Patel, K. Thalassinos, S. E. Slade et al., “A comparison of labeling and label-free mass spectrometry-based proteomics approaches,” Journal of Proteome Research, vol. 8, no. 7, pp. 3752–3759, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Shao, Y. Teng, R. Padia et al., “COP1 and GSK3β cooperate to promote c-Jun degradation and inhibit breast cancer cell tumorigenesis,” Neoplasia, vol. 15, no. 9, pp. 1075–1085, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. X. Jiao, S. Katiyar, N. E. Willmarth et al., “c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion,” Journal of Biological Chemistry, vol. 285, no. 11, pp. 8218–8226, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Ratnasinghe, P. J. Daschner, M. R. Anver et al., “Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible?” Anticancer Research, vol. 21, no. 3, pp. 2141–2147, 2001. View at Google Scholar · View at Scopus
  36. Y. Liu, J. Ludes-Meyers, Y. Zhang et al., “Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth,” Oncogene, vol. 21, no. 50, pp. 7680–7689, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Sui, S. Zhou, Y. Wang et al., “COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer,” Carcinogenesis, vol. 32, no. 5, pp. 667–675, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Salomoni, R. Bernardi, S. Bergmann, A. Changou, S. Tuttle, and P. P. Pandolfi, “The promyelocytic leukemia protein PML regulates c-Jun function in response to DNA damage,” Blood, vol. 105, no. 9, pp. 3686–3690, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Vallian, J. A. Gäken, E. B. Gingold, T. Kouzarides, K.-S. Chang, and F. Farzaneh, “Modulation of Fos-mediated AP-1 transcription by the promyelocytic leukemia protein,” Oncogene, vol. 16, no. 22, pp. 2843–2853, 1998. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Tchénio, M. Havard, L. A. Martinez, and F. Dautry, “Heat shock-independent induction of multidrug resistance by heat shock factor 1,” Molecular & Cellular Biology, vol. 26, no. 2, pp. 580–591, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. R. Dai, W. Frejtag, B. He, Y. Zhang, and N. F. Mivechi, “c-Jun NH2-terminal kinase targeting and phosphorylation of heat shock factor-1 suppress its transcriptional activity,” The Journal of Biological Chemistry, vol. 275, no. 24, pp. 18210–18218, 2000. View at Publisher · View at Google Scholar · View at Scopus
  42. N. E. Vilaboa, L. García-Bermejo, C. Pérez, E. de Blas, C. Calle, and P. Aller, “Heat-shock and cadmium chloride increase the vimentin mRNA and protein levels in U-937 human promonocytic cells,” Journal of Cell Science, vol. 110, part 2, pp. 201–207, 1997. View at Google Scholar · View at Scopus
  43. Y. Wu, X. Zhang, and Z. E. Zehner, “c-Jun and the dominant-negative mutant, TAM67, induce vimentin gene expression by interacting with the activator Sp1,” Oncogene, vol. 22, no. 55, pp. 8891–8901, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. Wu, X. Zhang, M. Salmon, X. Lin, and Z. E. Zehner, “TGFβ1 regulation of vimentin gene expression during differentiation of the C2C12 skeletal myogenic cell line requires Smads, AP-1 and Sp1 family members,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1773, no. 3, pp. 427–439, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Satelli and S. Li, “Vimentin in cancer and its potential as a molecular target for cancer therapy,” Cellular and Molecular Life Sciences, vol. 68, no. 18, pp. 3033–3046, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. K.-Y. Lee, L. Liu, Y. Jin, S.-B. Fu, and J. L. Rosales, “Cdk5 mediates vimentin ser56 phosphorylation during GTP-induced secretion by neutrophils,” Journal of Cellular Physiology, vol. 227, no. 2, pp. 739–750, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. K.-H. Chang, P. S. Multani, K.-H. Sun et al., “Nuclear envelope dispersion triggered by deregulated Cdk5 precedes neuronal death,” Molecular Biology of the Cell, vol. 22, no. 9, pp. 1452–1462, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Mehta, H. Katta, F. Alimirah et al., “Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells,” PLoS ONE, vol. 8, no. 6, Article ID e65113, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. S.-J. Chen, J. Luan, H.-S. Zhang et al., “EGFR-mediated G1/S transition contributes to the multidrug resistance in breast cancer cells,” Molecular Biology Reports, vol. 39, no. 5, pp. 5465–5471, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. C. P. Bagowski, M. Stein-Gerlach, A. Choidas, and A. Ullrich, “Cell-type specific phosphorylation of threonines T654 and T669 by PKD defines the signal capacity of the EGF receptor,” The EMBO Journal, vol. 18, no. 20, pp. 5567–5576, 1999. View at Publisher · View at Google Scholar · View at Scopus
  51. S. T. Eblen, “Regulation of chemoresistance via alternative messenger RNA splicing,” Biochemical Pharmacology, vol. 83, no. 8, pp. 1063–1072, 2012. View at Publisher · View at Google Scholar · View at Scopus